• Login
    View Item 
    •   UBIR Home
    • Research Data Collections
    • NIH Awards (public)
    • View Item
    •   UBIR Home
    • Research Data Collections
    • NIH Awards (public)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    MODULATION OF METHAMPHETAMINE ACTIONS IN THE CNS

    Thumbnail
    View/Open
    nih.html (233bytes)
    nih46.xml (5.036Kb)
    Date
    2011-04-18
    Author
    DUBOCOVICH, MARGARITA L Principal Investigator
    Metadata
    Show full item record
    Abstract
    DESCRIPTION (provided by applicant): The wide spread use of methamphetamine, causing abuse and dependence, is a significant medical, psychiatric, and public health concern. Identifying effective pharmacotherapies for the management of methamphetamine abuse and dependence is a research priority. Methamphetamine use is associated with behavioral sensitization, alterations in sleep and circadian rhythmicity, anxiety, mood changes and irritability either during abuse or upon withdrawal. The goal of this application is to investigate the potential of selective melatonin receptor ligands to attenuate the behavioral sensitization, increase reward behavior and circadian rhythm desynchronization associated with chronic methamphetamine abuse. Melatonin receptors (MTi, MT2) are emerging as targets for the modulation of dopamine-mediated signals, entrainment of disrupted behavioral circadian rhythms and sleep promotion. Neuropharmacological approaches will be used to investigate the role of melatonin receptor (MTi, MT2) activation by endogenous and exogenous melatonin in forebrain areas to modulate methamphetamine-induced locomotor sensitization, reward behavior and dopaminergic signaling through the CREB pathway. The involvement of CLOCK and NPAS-2 genes and melatonin receptors on the mechanism(s) by which chronic methamphetamine induce circadian rhythms disorganization and generates free running activity rhythms will also be investigated. Finally, we will develop mouse models to assess the potency of melatonin and dopamine ligands to entrain methamphetamine-induced suprachiasmatic nucleus independent free running rhythms. Results from these studies should provide the basis for the discovery and development of novel melatonin ligands to alleviate insomnia, circadian sleep disorders and depressive symptoms (endogenous depression) associated with the medical use and abuse of methamphetamine-like drugs.
    URI
    http://hdl.handle.net/10477/1098
    Collections
    • NIH Awards (public)

    To add content to the repository or for technical support: Contact Us
     

     

    Browse

    All of UBIRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    To add content to the repository or for technical support: Contact Us